<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383915</url>
  </required_header>
  <id_info>
    <org_study_id>06-123</org_study_id>
    <nct_id>NCT01383915</nct_id>
  </id_info>
  <brief_title>Clinical Risk State for Bipolar Disorder in Adolescents</brief_title>
  <official_title>Characterizing the Clinical Risk State for Bipolar Disorder in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: The purpose of the study is to characterize the at-risk phases preceding a first episode&#xD;
      of bipolar disorder and of schizophrenia, and to identify clinical and biological predictors&#xD;
      of the disease development.&#xD;
&#xD;
      Hypothesis a: Over 6-24 months, 25% of at-risk youth will develop the full manifestations of&#xD;
      Bipolar Disorder (BPD) or schizophrenia.&#xD;
&#xD;
      Hypothesis b: The symptoms utilized for characterizing the at-risk phase of BPD will&#xD;
      differentiate between individuals developing BPD and schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, naturalistic, cohort study aiming to characterizing the bipolar and psychotic&#xD;
      prodrome thoroughly with a variety of clinical and biological measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with development of a bipolar or schizophrenia disorder</measure>
    <time_frame>within 60 months</time_frame>
    <description>Diagnostic conversion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychopathology</measure>
    <time_frame>within 60 months</time_frame>
    <description>Psychopathology</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>inpatients</arm_group_label>
    <description>Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients consecutively admitted to the adolescent inpatient unit of the Zucker Hillside&#xD;
        Hospital, NY&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 12-18 years;&#xD;
&#xD;
          2. Sex: male or female;&#xD;
&#xD;
          3. Race/ethnicity: no restrictions;&#xD;
&#xD;
          4. Definite or suspected chart diagnosis of BP-II, BP-NOS, cyclothymia, MDD, depressive&#xD;
             disorder NOS, dysthymia or mood disorder NOS, schizophrenifiorm disorder or psychotic&#xD;
             disorder NOS;&#xD;
&#xD;
          5. Subject and parent (if subject&lt;18) willing and able to provide written, informed&#xD;
             consent/assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Estimated Premorbid IQ &lt; 70;&#xD;
&#xD;
          2. Meets DSM-IV criteria for BP-I or schizophrenia, pervasive developmental disorder,&#xD;
             autism spectrum disorders, current substance dependence;&#xD;
&#xD;
          3. History of medical condition known to affect the brain;&#xD;
&#xD;
          4. current group home affiliation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Correll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Zucker Hillside Hospital, Feinstein Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph U Correll, MD</last_name>
    <phone>7184704812</phone>
    <email>ccorrell@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Guinart, MD</last_name>
    <phone>718-470-4139</phone>
    <phone_ext>4139</phone_ext>
    <email>DGuinart@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital, NSLIJ</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph U Correll, MD</last_name>
      <phone>718-470-4812</phone>
      <email>ccorrell@northwell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Christoph U. Correll, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

